Tianjin Chase Sun PharmaceuticalLtd Second Quarter 2024 Earnings: EPS: CN¥0.03 (vs CN¥0.06 in 2Q 2023)

Simply Wall St · 08/30 22:30

Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥1.53b (down 13% from 2Q 2023).
  • Net income: CN¥90.1m (down 47% from 2Q 2023).
  • Profit margin: 5.9% (down from 9.7% in 2Q 2023).
  • EPS: CN¥0.03 (down from CN¥0.06 in 2Q 2023).
earnings-and-revenue-history
SZSE:300026 Earnings and Revenue History August 30th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Tianjin Chase Sun PharmaceuticalLtd Earnings Insights

Looking ahead, revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are up 3.1% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Tianjin Chase Sun PharmaceuticalLtd has 3 warning signs we think you should be aware of.